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Urate oxidase (EC 1.7.3.3) is an enzyme involved in purine metabolism which is used in the treatment of gout and as diagnostic
reagent for detection of uric acid. In order to produce this enzyme in large quantities for biotechnological purposes, the gene
coding for the Bacillus subtilis urate oxidase was cloned and heterologously expressed in Escherichia coli. Time course induction in
E. coli showed an induced protein with an apparent molecular mass of ∼60kDa. Soluble recombinant enzyme was puriﬁed in a
single-step procedure using Ni-NTA column. The enzyme was puriﬁed 2.1-fold with a yield of 56% compared to the crude extract.
MALDI-TOF analysis revealed an ion with a mass of 58675Da which is in agreement with the expected mass of the recombinant
protein.ThepuriﬁedenzymeshowedanoptimalpHandtemperatureof8.0and37
◦C,respectively,andretained90%ofitsactivity
after 72 hours of incubation at −20
◦C and 4◦C.
1.Introduction
Goutisadiseasecharacterizedbyjointandkidneyinﬂamma-
tion causedbyhighlevelsofuric acidin thebloodstream and
tissues. Uric acid is water soluble and is normally eliminated
by the kidneys in quantities between 600 and 700mg/day
when the organism receives a normal diet. Plasma concen-
trations of uric acid higher than 6mg/dL and 7mg/dL in
women and men, respectively, cause hyperuricemia. This
medical condition may be caused by a diet rich in proteins,
fat, and alcohol as well as hereditary factors (inborn errors of
purine-pyrimidine metabolism) [1]. There are other diseases
a s s o c i a t e dt oh y p e r u r i c e m i as u c ha st y p e2d i a b e t e sw h i c h ,
in the presence of higher levels of uric acid, causes insulin
absorption resistance in tissues, increase of nephropathy
progression, and tumor lysis syndrome (TLS) [2–4].
Urate oxidase (uricase, EC 1.7.3.4) is an enzyme with
copper bonds that catalyze the oxidative opening of the
purine ring of uric acid to form allantoin which is 5–10
times more soluble than uric acid [5, 6]. This enzyme can
be used therapeutically to reduce toxic urate accumulation.
Rasburicase (Fasturtec/Elitek) is a market name given to the
Aspergillus ﬂavus urate oxidase expressed in Saccharomyces
cerevisiae which has been approved for clinical use. Studies
showed that Rasburicase is more eﬀective than other drugs
in the treatment of hyperuricemia due to low incidence
of hypersensibility reaction [7, 8]. Urate oxidase is also
used as a reagent in clinical diagnostic kits for enzymatic
determination of uric acid. Native enzyme may be obtained
from several microorganisms of the genus Micrococcus, Bre-
vibacterium, Streptomyces, Candida, Bacillus, Pseudomonas,
Arthrobacter,a n dAspergillus [9–15]. Urate oxidase from
thermophilic Bacillus sp. TB-90 has been extensively studied
for diagnostic purposes since it exhibits high activity and
thermostability in a wide range of pHs [16]. Puriﬁed
recombinant Bacillus subtilis urate oxidase has been tested
with success in a biochip system for diagnostic purposes
[17]. In this case, the pucLM gene was cloned in-frame
with the maltose-binding protein (MPB) coding sequence
resulting in a large protein fusion (∼98kDa) which was
not signiﬁcantly overexpressed in Escherichia coli. This result
prompted us to employ a diﬀerent approach to improve the2 Journal of Biomedicine and Biotechnology
expression of B. subtilis urate oxidase in E. coli by using
a smaller 6x His tag which would also enable simple and
fast puriﬁcation of the recombinant enzyme for further
biochemical characterization and large-scale production.
2.MaterialsandMethods
2.1. Strains and Reagents. Bacillus subtilis subtilis LMD
69.3 was used as a source of the urate oxidase gene. For
heterologous expression, E. coli BL21 (DE3) pLysS and
the expression vector pET21a (Novagen) were used. Ni
Sepharose 6 Fast Flow (GE Healthcare) resin was used to
purify recombinant urate oxidase. Restriction enzymes and
the pGEM-T cloning vector were from Promega. Plasmid
extraction was performed by the use of QIAPrep Spin
Mini Kit (Qiagen). T4 DNA ligase was obtained from
New England Biolabs. Taq Platinum was purchased from
Invitrogen. Monoclonal antipoly histidine AP antibody was
purchased from Sigma. Other reagents were obtained from
standard commercial sources.
2.2. DNA Manipulations. B. subtilis chromosomal DNA was
extractedasdescribedelsewhere[18].Theurateoxidase cod-
ing sequence (1485pb) was obtained by PCR using primers
PUCL5 (5 -CGGATCCATGTTCACAATGGATGACCTG -3 )
and PUCL3 (5 -GCTCGAGGGCTTTCAGGCTCCGACAT-
3 ) which were designed based on the B. subtilis pucLM
gene sequence (GeneBank gi: 32468813). Primer PUCL5
contained a BamHI site (underlined) and the translation
initiation codon (bold), whereas PUCL3 incorporated an
engineered XhoI site (underlined). Ampliﬁcation was per-
formed using the following conditions: 30 cycles of 1 minute
at 94
◦C, 45 seconds at 50
◦C, and 1.5 minutes at 72
◦C. The
puriﬁed PCR product was ligated into pGEM-T resulting
in plasmid pGEMURI. The sequence of the cloned gene
was veriﬁed by automated DNA sequencing on the Genetic
Analyzer Mega Bace 1000 (GE Healthcare) using the Mega
Bace Dye Terminator kit. Plasmid pGEMURI was digested
with BamHI and XhoI and the pucLM gene was ligated into
pET21a digested with the same enzymes. Because primer
PUCL3 lacks a stop codon, the urate oxidase gene was
cloned in-frame with the 6x His tag coding sequence present
in pET21a. The resulting plasmid, pETURI, was used to
transform E. coli BL21 (DE3) pLysS.
2.3. Heterologous Expression. A single E. coli colony trans-
formed with pETURI was inoculated in 6mL Luria-Bertolin
(LB) medium containing 100μg/mL ampicillin and incu-
bated at 37
◦C with shaking (200–300rpm) overnight. Five
milliliters of this preculture were transferred to 50mL of LB
medium in a 250mL shake ﬂask. The culture was grown
under the same condition until OD600 reached 0.6 when
IPTG was added to a ﬁnal concentration of 1mM. One
milliliter samples were collected at diﬀerent intervals and cell
pellet was resuspended in 50μL of SDS-PAGE sample buﬀer
and boiled for 5 minutes prior to gel electrophoresis analysis.
Typically, 1–5μg total protein were loaded in each lane.
2.4. Western Blotting. Protein samples were separated on
12% SDS-PAGE gels and electroblotted onto PVDF mem-
brane. The membrane was blocked with 5% milk in 10mM
Tris-HCl with 150mM NaCl (pH 8.0) and 0.1% Tween 20
(TBST) for 2 hours at room temperature. The membrane
was then incubated for 2 hours at room temperature with
monoclonal mouse antipoly histidine AP antibody diluted 1
: 1000 in TBST. After three washes with TBST, bands were
visualized by using the NBT/BCIP detection method.
2.5. Recombinant Enzyme Puriﬁcation. In order to purify
and analyze the recombinant protein, one bacterial clone
was induced with 1mM IPTG in 100mL LB during 3
hours.Thecellswereharvestedbycentrifugationat5000rpm
for 20 minutes at 4◦C. Cell pellet (1.5g) was resuspended
in 2mL lysis buﬀe r( 1 0 m Mi m i d a z o l e ,5 0 m MN a H 2PO4
[pH 8.0], 300mM NaCl) and lysed by sonication (6 cycles
of 10 seconds of pulses at 45% amplitude—59W). The
suspension was centrifuged at 13000rpm for 10 minutes
and the supernatant loaded into an Ni-NTA column with
a volume of 1mL resin preequilibrated in lysis buﬀer. The
column was washed 8 times with 1mL wash buﬀer (20mM
imidazole, 50mM NaH2PO4 [pH 8.0], 300mM NaCl) and 4
times with 500μLe l u t i o nb u ﬀer (200mM imidazole, 50mM
NaH2PO4 [pH 8.0], 300mM NaCl). All fractions were stored
at 4◦C for further analysis.
2.6. MALDI TOF Mass Determinations. Molecular mass
determinations were performed on an Ultraﬂex II spectrom-
eter (Bruker Daltonics) using lyophilized sample dissolved
in Milli-Q water and mixed separately with two diﬀerent
saturated matrices solutions, α-cyano-4-hydroxycinnanic
acid, and 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic
acid). MALDI spectra were acquired in linear mode with
external calibration.
2.7. Urate Oxidase Assay. Urate oxidase degrades uric
acid forming hydrogen peroxide and allantoin. Hydrogen
peroxide reacts with 4-aminoantipyrine and 3,5-dichloro-
2-hydroxybenzenesulfonic acid and forms quinoneimine, a
r e dc o m p o u n dt h a ti sd e t e c t e db ya ni n c r e a s ei na b s o r b a n c e
at 555nm. The enzymatic reaction was carried out at
37
◦C and contained 200μL uric acid solution (10mg in
100mL of 10mM Tris-HCl, pH 8.0), 50μL distilled water,
and 50μL enzyme samples. After 15-minute reaction, the
reagent solution (4mM 4-aminoantipyrine, 2mM 3,5-
dichloro-2-hydroxybenzenesulfonic acid, 2mM horseradish
peroxidase, and 10mM Tris-HCl buﬀer) was added,
incubated at room temperature for 5 minutes, and
measured at 555nm. One unit of urate oxidase activity
was deﬁned as the amount of enzyme that catalyzes the
transformation of 1μm o lo fu r a t ep e rm i n u t ea t3 7
◦C
(pH 8.0). Urate oxidase activity was calculated using the
math formula found at the Kikkoman Biochemicals website
(http://www.kikkoman.co.jp/bio/e/common/rinsyou.html).
Protein concentration was determinate using the Bradford
method [19].Journal of Biomedicine and Biotechnology 3
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Figure 1: Small-scale expression and time course study of urate oxidase expression in E. coli. Comassie Blue stained 12% SDS-PAGE (a) and
respective Western blotting analysis (b) of urate oxidase induction in E. coli. Lane M, protein BenchMarker (Invitrogen); Lane 1, supernatant
ofuninducedcells;Lanes2–6,supernatantofinducedcellsafter15,30,60,90,and120minutes,respectively.Thearrowindicatestheposition
of the band corresponding to recombinant urate oxidase (rUox).
2.8. Enzyme Characterization. Enzyme activity as a function
of pH was tested with 50mM sodium citrate for the
followings values of pH: 2.5, 3.0, 4.5, 5.0; 50mM sodium
phosphate for pH values 6.0 and 7.0; 50mM Tris-HCl for
pH values 8.0, 9.0 and 10.0. The optimum temperature was
evaluated by measuring urate oxidase activity for 30 minutes
at diﬀerent temperatures: 25, 37, 40, 60, and 80
◦C. The
eﬀect of temperature on enzyme stability was determined
by measuring the residual activity after 0, 12, 24, 48 and 72
hours of preincubation in 10mM Tris-HCl (pH 8.0) at −20,
4a n d3 7
◦C.
3. Results
A ∼1.5kb amplicon corresponding to the B. subtilis pucLM
gene was successfully cloned, sequenced and transferred to
the bacterial expression vector pET21a (data not shown).
In order to analyze the kinetics of urate oxidase expression,
ac o l o n yo fE. coli cells harbouring pETURI was grown to
mid-log and induced with IPTG for 0, 15, 30, 60, 90, and
120 minutes. Samples analyzed by SDS-PAGE revealed a
∼60kDa induction band (Figure 1(a)). The size of this band
was consistent with the predicted mass of the recombinant
enzyme. Western blot analysis showed that the induction
band represented a protein which contained a 6x His tag
(Figure 1(b)). Two smaller (<50kDa) and less abundant
bands were also observed in the Western blot (Figure 1(b)).
Induction proﬁle showed a progressive accumulation of the
enzyme starting 15 minutes after addition of IPTG and
reaching the highest peak 90 minutes later. After induction
in 100mL, the cleared cell lysate was chromatographed in a
Ni-NTA resin column in order to purify recombinant urate
oxidase in a single-step. Fractions collected in diﬀerent steps
of puriﬁcation were analyzed by SDS-PAGE (Figure 2). In
order to optimize the puriﬁcation procedure of the enzyme
diﬀerent elution buﬀers containing increasing concentra-
tions of imidazole (50, 100, 150, 200mM) were tested
(data not shown). After elution with 200mM imidazole,
a predominant band with an apparent molecular mass of
∼60kDa was observed (Figure 2, lane 6). The data presented
in Table 1 shows that the enzyme was puriﬁed with a 2.1 fold
increaseinspeciﬁcactivitywithayieldof ∼58%ascompared
to the crude extract.
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Figure 2: Recombinant enzyme puriﬁcation. Fractions collected
before and after Ni-NTA chromatography were visualized on 12%
SDS-PAGE. Lane M, protein BenchMarker (Invitrogen); Lane 1,
crude extract of uninduced E. coli cells; Lane 2, crude cell extract
after induction for 3 hours; Lane 3, cellular extract (input); Lane
4, ﬂow-through; Lane 5, washing step (20mM imidazole); Lane
6, puriﬁed urate oxidase (∼30.5μg) after elution with 200mM
imidazole.
MALDI-TOF/MS analysis of the puriﬁed enzyme frac-
tion revealed two major ions M+H+ = 58675Da and its
double charged M+2H+ = 29338.1Da (Figure 3). The eﬀects
of pH and temperature on enzyme activity are shown in
Figures 4(a) and 4(b), respectively. Puriﬁed urate oxidase
showed maximum activity at pH 8.0 and 37
◦C( Figure 4(b)).
As shown in Figure 5, the residual activity was practically
constant at −20
◦Ca n d4 ◦C after a 72 hours incubation
period but was signiﬁcantly aﬀected by incubation at 37
◦C.
4. Discussion
Urate oxidase is a enzyme conserved in many species ranging
from microorganisms to mammals; however, primates have
lost this activity as consequence of evolutionary gene muta-
tions [20, 21]. This enzyme catalyzes the oxidative reaction
that converts urate to allantoin, a more soluble and easily
excreted compound. Due to this property urate oxidase may
be used for both therapeutical and diagnostic purposes [22].4 Journal of Biomedicine and Biotechnology
Table 1: Summary of the puriﬁcation steps.
Step Total activity Total protein Speciﬁc activity Puriﬁcation Yield
(IU) (mg) (IU/mg) (fold) (%)
Crude Extract 54.0 3.0 18.0 1 100
Ni-NTA 31.2 0.8 39.0 2.1 56
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Figure 3: Mass spectometry. MALDI-TOF/MS spectrum of recom-
binant urate oxidase using sinapinic acid as matrix showed two
related ions for the same polypeptide chain, M+2H+ = 29338.1Da
and M+H+ = 58675Da.
Many sources of urate oxidase are available, but commercial
p r o d u c t i o nm a yb eh a m p e r e db yl o wp r o d u c t i v i t ya n dd i f -
ﬁculties in protein puriﬁcation for clinical applications [22,
23]. DNA technology has been employed to overcome these
diﬃculties by expressing urate oxidase genes in heterologous
systems [24].
In B. subtilis the genes for purine degradation are
clustered at positions 284 to 285
◦ in the genome map
[25, 26]. Mutational analysis of this region showed that
inactivation of pucLM resulted in a defect in the utilization
of guanosine, hypoxanthine, and uric acid and was thus
proposed to code for urate oxidase [26]. Although the
protein coded from the puLM gene shows amino acid
identity to other urate oxidases, this similarity is restricted
to the C-terminal domain (amino acids 171–494) [26]w i t h
the highest identities being with Bacillus sp. TB-90 (66%),
Bacillus clausii (63%), and Bacillus fastidiosus (55%). It has
been proposed that the ﬁrst 170 amino acids correspond to
a peroxide reductase domain that could be involved in the
removal of hydrogen peroxide, a product of the oxidation of
uric acid to allantoin catalyzed by urate oxidase [26]. Unlike
eukaryotic urate oxidases and similar to Bacillus sp. TB-90,
the B. subtilis enzyme does not have the typical type 2 copper
binding motif H-X-H-X-F [27].
In this work, the pucLM was successfully expressed in
E. coli in a soluble and active form. This result is particular
important for the commercial production of this enzyme
since it eliminates the laborious denaturing/refolding steps
often necessary to solubilize proteins present as inclusion
bodies. Furthermore, the strategy used in this work involved
the fusion of B. subtilis urate oxidase to a 6x His tag
in order to allow simple one-step puriﬁcation using Ni-
NTA column. A derivation of this method using Ni ion-
chelating magnetic beads to increase yield was reported for
the puriﬁcation of recombinant Bacillus sp. TB-90 urate
oxidase [28]. The results presented in Table 1 show that the
recombinant enzyme was puriﬁed almost to homogeneity
and the yield was about 58% as compared to the crude
extract. This yield was close to that reported for commercial
Rasburicase (61%) and native B. subtilis urate oxidase (67%)
[28, 29]. The smaller protein contaminants that copuriﬁed
with the recombinant enzyme represent minor breakdown
products because they were recognized by the antipoly
histidine antibody (Figure 1(b)). The recombinant enzyme
was submitted to biochemical characterization (molecular
mass determination, thermostability, optimum temperature
and pH) and in vitro enzymatic activity. The experimental
molecular mass value of 58675Da obtained by MALDI-
TOF/MS for the recombinant enzyme is close to the theoret-
ical values calculated for the predicted recombinant protein
(58.9kDa). The optimum temperature (37
◦C) and pH (8.0)
were similar to that observed with A. ﬂavus urate oxidase
produced in E. coli [30] and the B. subtilis MPB-uricase
fusion protein [17]. In enzymatic assays the B. subtilis urate
oxidase exhibited a speciﬁc activity of 39IU/mg protein, a
value higher than those observed for other urate oxidase
described in the literature under optimal conditions. For
example, native B. subtilis urate oxidase speciﬁc activity
was 5.29IU/mg protein, the speciﬁc activity for the A.
ﬂavus urate oxidase expressed in E. coli was 26.96IU/mg
and the commercial Rasburicase was 26.98IU/mg protein
[30]. Thermostability is considered an important and useful
criterion for industrial application of enzymes. The stability
of the recombinant enzyme at the temperatures used to store
commercial enzymatic diagnostic kits (−20
◦Ca n d4 ◦C) was
evaluated and the enzyme kept 80% of its residual activity
after 72 hours of pre-incubation. However, at 37
◦C, 50%
of the residual activity was lost after 12 hours which is in
agreement with the Rasburicase half life of 19 hours reported
in humans [30, 31]. It has been proposed that the human
body temperature is responsible for the shorter circulating
half-time exhibited by recombinant urate oxidase [30, 31].
The results presented in this work showed the feasibility
of producing soluble recombinant urate oxidase at high
levels. The purity of the enzyme together with its high
activity and thermostability shows that the production of the
B.subtilisurateoxidaseinE.colishouldbeconsideredforthe
development of diagnostic kits and for clinical purposes.Journal of Biomedicine and Biotechnology 5
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Figure 4: Eﬀect of pH and temperature on enzyme activity. Puriﬁed urate oxidase was incubated under diﬀerent pHs (a) and temperatures
(b) and assayed as described in Section 2.
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Figure 5: Thermal stability. Puriﬁed enzyme was pre-incubated
at −20
◦C, 4◦Ca n d3 7
◦C for the indicated times, and assayed at
37
◦C. Residual activity corresponds to the percentage of activity
determined for the nonincubated samples.
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